MADRIGAL PHARMACEUTICALS, INC. (MDGL) is a publicly traded company in the Unknown sector. Across all available filings, 29 corporate insiders have executed 717 transactions totaling $865.6M, demonstrating a bearish sentiment with -$583.5M in net insider flow. The most recent transaction on Jan 26, 2026 involved a transaction of 4,000 shares valued at $0.
No significant insider buying has been recorded for MDGL in the recent period.
No significant insider selling has been recorded for MDGL in the recent period.
Based on recent SEC filings, insider sentiment for MDGL is bearish with an Insider Alignment Score of 16/100 and a net flow of -$583.5M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at MADRIGAL PHARMACEUTICALS, INC. (MDGL) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 29 insiders are actively trading MDGL stock, having executed 717 transactions in the past 90 days. The most active insider is Fred B. Craves (Executive), who has made 45 transactions totaling $219.4M.
Get notified when executives and directors at MDGL file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 26, 2026 | S. Levy Richard | Executive | Option Exercise | 4,000 | $N/A | $0 | |
| Jan 26, 2026 | S. Levy Richard | Executive | Option Exercise | 4,000 | $16.46 | $65.8K | |
| Jan 26, 2026 | John Sibold William | Executive | Sale | 1,577 | $492.42 | $776.5K | Large |
| Jan 26, 2026 | Taub Rebecca | Executive | Sale | 647 | $492.42 | $318.6K | |
| Jan 20, 2026 | Taub Rebecca | Executive | Sale | 2,238 | $490.77 | $1.1M | Large |
| Jan 15, 2026 | Thakkar Rita | Chief Accounting Officer | Award | 1,826 | $N/A | $0 | |
| Jan 15, 2026 | Thakkar Rita | Chief Accounting Officer | Award | 2,398 | $N/A | $0 | |
| Jan 9, 2026 | A. Friedman Paul | Executive | Option Exercise | 280 | $N/A | $0 | |
| Jan 9, 2026 | A. Friedman Paul | Executive | Sale | 280 | $551.24 | $154.3K | |
| Jan 9, 2026 | A. Friedman Paul | Executive | Option Exercise | 280 | $15.80 | $4.4K | |
| Dec 10, 2025 | Taub Rebecca | Executive | Sale | 369 | $548.56 | $202.4K | |
| Dec 10, 2025 | Taub Rebecca | Executive | Option Exercise | 18,650 | $15.80 | $294.7K | |
| Dec 10, 2025 | Taub Rebecca | Executive | Sale | 491 | $547.76 | $269.0K | |
| Dec 10, 2025 | Taub Rebecca | Executive | Gift | 5,455 | $N/A | $0 | |
| Dec 10, 2025 | Taub Rebecca | Executive | Sale | 486 | $550.07 | $267.3K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 351 | $724.6M | 80.9% |
Purchase(P) | 217 | $141.0M | 15.7% |
Exercise(M) | 66 | $28.2M | 3.2% |
Payment(F) | 8 | $1.8M | 0.2% |
Award(A) | 47 | $0 | 0.0% |
Gift(G) | 7 | $0 | 0.0% |
Other(J) | 21 | $0 | 0.0% |
Insider selling pressure at MADRIGAL PHARMACEUTICALS, INC. has increased, with 29 insiders executing 717 transactions across all time. Total sales of $724.6M significantly outpace purchases of $141.0M, resulting in a net outflow of $583.5M. This selling activity appears largely discretionary, which may warrant closer attention from investors.